Mov Disord Vol 35, Suppl 1 Archives - Page 62 of 149 - MDS Abstracts

MDS Virtual Congress 2020
The role of the disorders in interaction between visual and oculomotor systems and their MRI correlation in patients with camtocormia in Parkinson’s disease
O. Alenikova, S. Likhachev (Minsk, Belarus)
Objective: To investigate the relationship between the visual function state, oculomotor parameters and MRI morphometry data in PD patients with and without camtocormia. Background: Interacting…
MDS Virtual Congress 2020
Predictive factors of serious falls in Parkinson’s disease
H. Matsumoto, M. Shiraishi, S. Tochimoto, K. Tanaka, K. Uchino, Y. Hasegawa (Kawasaki, Japan)
Objective: We aimed to determine predictive factors for serious falls in PD by long term follow-up for four years after comprehensive evaluation both in physical…
MDS Virtual Congress 2020
Interaction between genetic variants and serum levels of organochlorine pesticides contributes to Parkinson’s disease
S.Q Xu, X.D Yang, Y.W Qian, Q. Xiao (Shanghai, China)
Objective: To evaluate the association between serum levels of pesticides and PD and the interactions of genetic variants with pesticides on PD risk. Background: There…
MDS Virtual Congress 2020
Rates of Pharmacological Treatment of Neuropsychiatric Symptoms in Early Parkinson’s Disease
C. Kulick-Soper, C. Caspell-Garcia, C. Coffey, M. Picillo, D. Weintraub, N. Dahodwala (Philadelphia, PA, USA)
Objective: To determine the rates of pharmacological treatment for neuropsychiatric symptoms (NPS) in patients with early Parkinson’s disease (PD), and identify predictors of under-treatment. Background:…
MDS Virtual Congress 2020
Comparative evaluation of the biomechanical analysis of gait in patients with Parkinson’s disease vs controls of the Zambrano Hellion Hospital
L.z Alvarado, H. Martínez, A. Sarreon, L. Guerrero, C. Cámara (SPGG, Mexico)
Objective: Evaluate the usefulness of biomechanical assessment of gait in patients with Parkinson's disease. Background: There are no biomarkers or objective measurements accepted to determine…
MDS Virtual Congress 2020
In vivo imaging of presynaptic terminal loss in early Parkinson’s disease
A. Delva, D. Van Weehaeghe, M. Koole, K. Van Laere, W. Vandenberghe (Leuven, Belgium)
Objective: To determine the magnitude and anatomical extent of presynaptic terminal damage in early Parkinson’s disease (PD) in vivo, we performed a PET study with…
MDS Virtual Congress 2020
Improvement for Gait Disorders in Parkinson’s Disease Through Novel Comprehensive Treatment (IMPROVE study): A Prospective, Open-label, Randomized Controlled Clinical Trial
X. Huang, L. Chen, G. Cai, J. Xin, Y. Yang, Q. Ye (Fuzhou, China)
Objective: We conducted a prospective, open-label, randomized controlled clinical trial (clinical trial identifier: ChiCTR1900023466) to evaluate the effects of different combinations of comprehensive treatment on…
MDS Virtual Congress 2020
Effect of home-based functional training program on enhancing gross and fine upper extremity function in people with Parkinson’s disease – a randomized controlled trial
M.Y Mak, L.J Ren, I.K Wong-Yu (Hong Kong SAR, China)
Objective: The present study aimed to examine the effect of functional training on enhancing the gross and fine upper limb extremity function in people with…
MDS Virtual Congress 2020
Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)
R. Pahwa, J. Aldred, N. Gupta, E. Terasawa, V. Garcia Horton, D. Macaulay, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, S. Isaacson (Kansas City, KS, USA)
Objective: To assess the speed of on-time onset and characterize the patterns of motor states throughout the day in advanced Parkinson’s disease patients treated with…
MDS Virtual Congress 2020
Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains
M. Siddiqui, V. Evidente, P. Bhargava, B. Navia, E. Pappert (Winston-Salem, NC, USA)
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…